Tibsovo®
FOR IMMEDIATE RELEASE:
Tibsovo® (ivosidenib) Now Available from Onco360 for the Treatment of Adult Patients with IDH1-mutant Acute Myeloid Leukemia or Previously Treated, IDH1-mutant Metastatic Cholangiocarcinoma
Louisville, KY – Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected by Servier Pharmaceuticals to be a specialty pharmacy partner for TIBSOVO® (ivosidenib), which is an isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with a susceptible IDH1 mutation as detected by an FDA-approved test with newly diagnosed acute myeloid leukemia (AML) in combination with azacitidine or as monotherapy in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy, relapsed or refractory AML, or locally advanced or metastatic cholangiocarcinoma that has been previously treated.
“Onco360 is honored to partner with Servier Pharmaceuticals and become a specialty pharmacy provider for Tibsovo patients,” said Benito Fernandez, Chief Commercial Officer, Onco360. “We are dedicated to supporting the highly specialized needs of patients battling IDH1-mutant AML or cholangiocarcinoma across the United States.”
According to the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) program, it is estimated that 20,050 new cases of AML will be diagnosed in 2022 in the United States with a corresponding 11,540 deaths in 2022. Approximately 6-9% of AML cases are found to have IDH1 mutations. The median age at the time of initial AML diagnosis is 68 years. The five-year overall survival for AML patients is only 30.5%.1,2
According to the American Cancer Society, approximately 8,000 patients are diagnosed with cholangiocarcinoma, a bile duct cancer, on an annual basis in the United States. Approximately 13% of cholangiocarcinoma cases are found to have IDH1 mutations. The average age at the time of initial cholangiocarcinoma diagnosis is 70-72 years old dependent upon tumor location. The five-year overall survival for cholangiocarcinoma patients, regardless of cancer stage, is only 9-10% dependent upon tumor location.3,4
TIBSOVO® is commercialized by Servier Pharmaceuticals. Please see the full prescribing information for TIBSOVO at Tibsovopro.com.
References:
- 1 All statistics from Acute Myeloid Leukemia — Cancer Stat Facts accessed on 8/15/2022
- 2 All statistics from pdf (nccn.org) accessed on 8/15/22
- 3 All statistics from Statistics About Bile Duct Cancer | Cholangiocarcinoma Stats accessed on 8/15/22
- 4 All statistics from pdf (nccn.org) accessed on 8/15/22
Media Contact:
Benito Fernandez, Chief Commercial Officer
[email protected]
516-640-1332